WV SB594

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational drugs, biological products, or devices (such as gene therapy or neoantigen vaccines) that are customized based on their genetic profile, after exhausting FDA-approved options

Requires written informed consent documenting the patient's condition, understanding of risks including potential death, acknowledgment that insurance may not cover treatment costs, and agreement from the treating physician

Protects health care providers from license revocation, suspension, or disciplinary action by licensing boards solely for recommending individualized investigational treatments to eligible patients

Shields manufacturers and others involved in patient care from private lawsuits for harm caused by individualized treatments, provided they acted in good faith and exercised reasonable care

Prohibits state officials from blocking eligible patient access to these treatments and exempts heirs from liability for outstanding treatment-related debt if the patient dies; effective date is January 1, 2026